Anavex Life Sciences (AVXL) announced the appointment of Wolfgang Liedtke, MD PhD, as Senior Vice President, Global Head of Neurology. Liedtke is a board-certified neurologist, who brings more than 25 years of extensive experience in developing and delivering innovative medicines in a broad range of CNS diseases, including genetic medicines and global therapeutic development. Most recently he was Chair of Neurology at Regeneron (REGN).
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVXL:
- Anavex receives FDA feedback on Alzheimer’s disease program
- Anavex submits request for EMA to re-examine its opinion on blarcamesine
- Promising Therapeutic Potential of Blarcamesine Sparks Buy Rating for Anavex Life Sciences
- Anavex participates in a conference call with H.C. Wainwright
- Anavex announces negative CHMP opinion on blarcamesine MAA